PRINCETON, N.J. & PARIS--(BUSINESS WIRE)--STENTYS (Paris:STNT)(FR0010949404 — STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announced that the Company’s Drug-Eluting stent received CE Mark for treatment of below-the-knee (BTK) arteries, making STENTYS’ product the first self-expanding and drug-eluting stent with regulatory approval in Europe for this indication.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
